Introducing GNEprop: A Deep Learning Model for Antibiotic Discovery

Today in Nature Biotechnology, our scientists, in collaboration with Mila - Institut québécois d'intelligence artificielle and NVIDIA Healthcare, introduce GNEprop, an AI-powered model designed to help scientists identify novel compounds with potential antimicrobial activity beyond the established chemical space. By combining AI with experimental science, we can better identify entirely new mechanisms of action for antibiotic activity, helping tackle one of the greatest global health challenges: antimicrobial resistance. Learn more: http://spr.ly/6046AhlsE #AMR #Innovation #LabInALoop

Antimicrobial resistance is one of the greatest threats to global health. Addressing this issue requires creative solutions and collaborative efforts. At Roche and Genentech, we are harnessing the power of advanced technologies, such as artificial intelligence, to transform the way antibiotics are discovered. Our colleagues at Genentech have developed GNEprop, a revolutionary deep learning algorithm designed to speed up the identification of promising antibiotic compounds. By seamlessly blending AI with laboratory science, we are pushing the boundaries of what is possible in our shared mission to combat AMR. Together, we are committed to innovating and addressing one of the most pressing challenges in healthcare. #AMR #Innovation #Roche #Genentech #LabInALoop #RocheAMR

Every year, millions of lives are threatened by bacterial infections that no longer respond to treatment. The rise of antimicrobial resistance (#AMR) shows us that innovation is not just about progress, it is about life. At Roche and Genentech, we believe that continuous investment in scientific progress can rise to this challenge. That’s why our teams are combining creativity, technology, and relentless curiosity to find new solutions. One such answer is GNEprop, a deep learning algorithm developed by our Genentech colleagues that can predict which compounds might have antibiotic potential. By merging the power of AI with traditional laboratory research, GNEprop enables us to uncover new possibilities faster than ever before. Protecting global health means daring to imagine new ways forward and turning that imagination into action. #AMR #Innovation #Roche #Genentech #LabInALoop #RocheAMR

Biofilm research is booming and for good reason. These microbial communities are at the heart of challenges in: Healthcare (persistent infections, AMR) Industry (equipment damage, product contamination) Environment (pollution, ecosystem balance) But they are also inspiring groundbreaking innovation: 🔬 AI-powered imaging to map biofilm growth in real time, 💊 Nanoparticles and smart materials to disrupt biofilm defenses and 🧬 Synthetic biology approaches to design “good biofilms” for beneficial use. Biofilms are no longer just a problem, they are a platform for discovery. The question is: how do we balance controlling harmful biofilms while leveraging beneficial ones? #Biofilms #Research #Innovation #Biotech #SyntheticBiology #Nanotechnology #AI #FutureOfScience

🤝 Engineering the Future of AI-Driven Biomedical Innovation. Digital Ether Computing and BioICAWtech 💊 are joining forces to accelerate innovation across artificial intelligence, biomedical analytics, and precision medicine. This collaboration brings together complementary capabilities to advance: • Drug discovery and repurposing • Protein-aware molecular design • Sequencing and multi-omics integration • Personalized therapy insights and recommendations Together, we are building a more intelligent, integrated, and agile future for biotechnology and therapeutic development. #AI #HealthcareInnovation #DrugDiscovery #Bioinformatics #Biotech #PrecisionMedicine #DigitalEtherComputing #BioICAWtech

Great to see our client LinkGevity making headlines🧬 Researchers call for ‘system-level’ approach to combat aging. New paper argues broad impact of GLP-1s supports the development of therapies that target entire systems rather than isolated dysfunctions. The necrosis concept is already being taken forward by LinkGevity, a biotechnology company co-founded by Kern. Guided by its founder’s Blueprint theory, the company applies AI to map the molecular “patho-pathways” that drive aging, integrating semantic data analysis and computational modelling to identify systemic biological triggers and predict therapeutic targets. Read More: https://lnkd.in/e-KCbfW4

What will the synthetic biology industry look like in 2040? At the BioInnovation Summit during the 2025 iGEM Grand Jamboree, leaders in biotechnology, AI, and industry will explore this question in the session “Synthetic Biology Industry 2040”. The discussion will examine the forces shaping the future of synbio, from breakthroughs in healthcare, consumer goods and industrial biotech, to the hurdles that still limit scale and adoption. Panelists will share insights on what it will take for synthetic biology to become a resilient, global industry with real-world impact. Speakers: - Xavier Godron, CTO of DNA Script; - Sibylle Jäger Innovation Manager for Green Sciences Incubator at L'OREAL R&I (L'Oréal); - Genya Dana, Architect of Global Bioeconomy Strategies. For additional information about the BioInnovation Summit: https://lnkd.in/ebVHdcBp 🎟️ Tickets for the iGEM Grand Jamboree, which include universal access to all events, including the BioInnovation Summit, are available now: https://lnkd.in/dzMPgkvX  #iGEM2025 #BioInnovationSummit

AI-designed proteins and biosecurity: innovation meets risk Recent reports highlight how AI-assisted protein design can now create synthetic sequences that bypass current biosecurity screening — a wake-up call for science and policy alike. While the technology could revolutionize drug discovery, it also introduces dual-use risks: faster innovation on one hand, and potential misuse on the other. The message is clear — AI in biology needs proactive governance. Screening standards, international oversight, and AI-aware safeguards must evolve as fast as the tech itself. Read more: https://lnkd.in/dXDAh_Jw #Biosecurity #AI #SyntheticBiology #LifeSciences #AIEthics #Policy #DualUseAIAI

AI meets protein interaction 🤖🧬 Congrats to Bruno Correia's lab from EPFL on their new Nature paper introducing BindCraft, an AI platform that can potentially design functional protein binders in a single shot. Built on AlphaFold, which predicts how natural proteins fold, BindCraft is creating proteins engineered to bind to chosen targets with nanomolar precision. The team showed PoC validation across Cas9, AAV capsids, and even allergen blockers, showing functional impact, not just predictions. These are still early days but the wave of AI-driven synthetic biology seems like it could reshape our world. Accelerate the discovery of new drugs, create personalized therapies, design novel materials, produce cleaner energy, and even improve recycling. 🔗 https://lnkd.in/eFXQWTmT

#GrowNY finalist ERGO combines AI and biotechnology to unlock the full power of plant cells. Their proprietary platform, EUKARYA, combines artificial intelligence, genomics, high-throughput screening and metabolic engineering to identify and optimize plant cell lines for targeted compounds. Learn more about Ergo and the other year 7 finalists at https://lnkd.in/gJY7qg6J